Abstract: Disclosed are a new AXL-targeting monoclonal antibody and antibody-drug conjugate. Also disclosed is a method for preparing said antibody and antibody-drug conjugate. The AXL antibody of the present invention can bind with purified human AXL protein and multiple AXL on tumor cell surface with high effectiveness and high specificity. Said humanized antibody also has high affinity and low immunogenicity. Said AXL antibody-drug conjugate has markable performance against tumors having high AXL expression.

Abstract: Three dimensional object reconstruction for sensor simulation includes performing operations that include rendering, by a differential rendering engine, an object image from a target object model, and computing, by a loss function of the differential rendering engine, a loss based on a comparison of the object image with an actual image and a comparison of the target object model with a corresponding lidar point cloud. The operations further include updating the target object model by the differential rendering engine according to the loss, and rendering, after updating the target object model, a target object in a virtual world using the target object model.

Abstract: Real world object reconstruction and representation include performing operations that include sampling locations along a camera ray from a virtual camera to a target object to obtain a sample set of the locations along the camera ray. For each location of the at least a subset of the sample set, the operations include determining a position of the location with respect to the target object, executing, based on the position, a reflectance multilayer perceptron (MLP) model, to determine an albedo and material shininess for the location, and computing a radiance for the location and based on a viewing direction of the camera ray using the albedo and the material shininess. The operations further includes rendering a color value for the camera ray by compositing the radiance across the first sample set.

Abstract: Techniques for generating testing data for an autonomous vehicle (AV) are described herein. A system can obtain sensor data descriptive of a traffic scenario. The traffic scenario can include a subject vehicle and actors in an environment. Additionally, the system can generate a perturbed trajectory for a first actor in the environment based on perturbation values. Moreover, the system can generate simulated sensor data. The simulated sensor data can include data descriptive of the perturbed trajectory for the first actor in the environment. Furthermore, the system can provide the simulated sensor data as input to an AV control system. The AV control system can be configured to process the simulated sensor data to generate an updated trajectory for the subject vehicle in the environment. Subsequently, the system can evaluate an adversarial loss function based on the updated trajectory for the subject vehicle to generate an adversarial loss value.

Abstract: Systems and methods for improved vehicle-to-vehicle communications are provided. A system can obtain sensor data depicting its surrounding environment and input the sensor data (or processed sensor data) to a machine-learned model to perceive its surrounding environment based on its location within the environment. The machine-learned model can generate an intermediate environmental representation that encodes features within the surrounding environment. The system can receive a number of different intermediate environmental representations and corresponding locations from various other systems, aggregate the representations based on the corresponding locations, and perceive its surrounding environment based on the aggregated representations. The system can determine relative poses between the each of the systems and an absolute pose for each system based on the representations.

Abstract: Systems and methods for vehicle-to-vehicle communications are provided. An adverse system can obtain sensor data representative of an environment proximate to a targeted system. The adverse system can generate an intermediate representation of the environment and a representation deviation for the intermediate representation. The representation deviation can be designed to disrupt a machine-learned model associated with the target system. The adverse system can communicate the intermediate representation modified by the representation deviation to the target system. The target system can train the machine-learned model associated with the target system to detect the modified intermediate representation. Detected modified intermediate representations can be discarded before disrupting the machine-learned model.

Abstract: A method for preparing a new crystalline form of ?-aminobutyric acid, including the steps of: S1: preparing a ?-aminobutyric acid solution at an initial concentration of 0.5-1.0 g/mL by adding crude ?-aminobutyric acid to water; adding an additive to the ?-aminobutyric acid solution, raising the temperature to 50-80° C., stirring to produce a clear solution; and S2: obtaining a suspension by evaporating water from the product of S1 under reduced pressure and at 50-80° C.; obtaining a wet product by filtering the suspension; drying the wet product to obtain the new crystalline form of ?-aminobutyric acid. The preparation method of the new crystalline form of ?-aminobutyric acid is simple, easy to operate, low in energy consumption, economical and environmentally friendly. It is suitable for large-scale industrial production.

Abstract: The present invention discloses a ?-aminobutyric acid hemihydrate crystal, its molecular formula is C4H9NO2.0.5H2O. It also discloses a method of preparing a ?-aminobutyric acid hemihydrate crystal, including first adding crude ?-aminobutyric acid to water to prepare a ?-aminobutyric acid suspension at an initial concentration of 1.2-2.0 g/mL; then stirring the suspension at a constant temperature of 5-10° C. for 6-12 hours, followed by filtering and drying to obtain the ?-aminobutyric acid hemihydrate crystal. The ?-aminobutyric acid hemihydrate crystal is stable, does not easily absorb moisture and agglomerate, and is convenient for further processing and use. The crystal has a large main particle size, uniform particle size distribution, high bulk density, good flowability, and a purity of ?99%. The preparation method of the crystal according to the present invention is simple, easy to operate, highly efficient and low in energy consumption, and is suitable for large-scale industrial production.

Abstract: A method for preparing a new crystalline form of ?-aminobutyric acid, including the steps of: S1: preparing a ?-aminobutyric acid solution at an initial concentration of 0.5-1.0 g/mL by adding crude ?-aminobutyric acid to water; adding an additive to the ?-aminobutyric acid solution, raising the temperature to 50-80° C., stirring to produce a clear solution; and S2: obtaining a suspension by evaporating water from the product of S1 under reduced pressure and at 50-80° C.; obtaining a wet product by filtering the suspension; drying the wet product to obtain the new crystalline form of ?-aminobutyric acid. The preparation method of the new crystalline form of ?-aminobutyric acid is simple, easy to operate, low in energy consumption, economical and environmentally friendly. It is suitable for large-scale industrial production.

Abstract: The present invention discloses a ?-aminobutyric acid hemihydrate crystal, its molecular formula is C4H9NO2.0.5H2O. It also discloses a method of preparing a ?-aminobutyric acid hemihydrate crystal, including first adding crude ?-aminobutyric acid to water to prepare a ?-aminobutyric acid suspension at an initial concentration of 1.2-2.0 g/mL; then stirring the suspension at a constant temperature of 5-10° C. for 6-12 hours, followed by filtering and drying to obtain the ?-aminobutyric acid hemihydrate crystal. The ?-aminobutyric acid hemihydrate crystal is stable, does not easily absorb moisture and agglomerate, and is convenient for further processing and use. The crystal has a large main particle size, uniform particle size distribution, high bulk density, good flowability, and a purity of ?99%. The preparation method of the crystal according to the present invention is simple, easy to operate, highly efficient and low in energy consumption, and is suitable for large-scale industrial production.

Abstract: The present application relates to polymorphs of Compound A: or a stereoisomer thereof, and methods of preparation and use thereof.

Abstract: It discloses a new industrial crystallization method of Cefuroxime Sodium, wherein supercritical fluid extraction technology and traditional crystalline technology are combined to realize the recrystallization of Cefuroxime Sodium. Processes such as extraction, adsorption, crystallization and drying are carried out with a supercritical fluid, a solvent, an extraction cell and a crystallization tank to realize the recrystallization of Cefuroxime Sodium under a specific pressure at a specific temperature.

Abstract: A novel crystalline form is defined by diffraction angle 2?° of X-ray powder diffraction pattern and characteristic peak of differential scanning calorimetry (DSC). The novel crystalline form of Cefamandole Nafate is prepared as follows: adding Cefamandole Nafate in solid state to an organic solvent to form a suspension with a concentration of 0.04˜0.3 g/ml, stirring the suspension at 40˜50° C. for a period of time, and then cooling to 5˜15° C. at certain cooling rate, continuing to stir for a period of time, then suction filtrating the obtained suspension, the resulting filer cake is Cefamandole Nafate as wet product, which is dried to constant weight to provide the novel crystalline form of Cefamandole Nafate as final product.

Abstract: A novel crystalline form is defined by diffraction angle 2?° of X-ray powder diffraction pattern and characteristic peak of differential scanning calorimetry (DSC). The novel crystalline form of Cefamandole Nafate is prepared as follows: adding Cefamandole Nafate in solid state to an organic solvent to form a suspension with a concentration of 0.04˜0.3 g/ml, stirring the suspension at 40˜50° C. for a period of time, and then cooling to 5˜15° C. at certain cooling rate, continuing to stir for a period of time, then suction filtrating the obtained suspension, the resulting filer cake is Cefamandole Nafate as wet product, which is dried to constant weight to provide the novel crystalline form of Cefamandole Nafate as final product.

Abstract: This invention provides a new preparation method of Clopidogrel Hydrogen Sulfate spherical crystal form I, using single 2-butanol as solvent, controlling the concentration, addition way and addition speed of sulfuric acid used to salify to shorten the process time, thus separating out Clopidogrel Hydrogen Sulfate from solution system stably with spherality. And the Clopidogrel Hydrogen Sulfate obtained complies with the requirements of the follow-up process on residual solvent, bulk density and mobility.

Abstract: A novel crystalline form is defined by using diffraction angle 2?° of X-ray powder diffraction pattern and characteristic peaks of differential scanning calorimetry (DSC). Pantoprazole Sodium solid is added to an alcohol solvent to form a suspension with a concentration of 0.05˜0.2 g/mL, and then an antioxidant is added to the suspension, completely dissolving the solid at a temperature of 15˜35° C., and a solventing-out agent is dropwise added to the solution under the application of ultrasonic wave, wherein the amount of the solventing-out agent is 3˜10 times (in volume) of the alcohol solvent; followed by cooling the solution down to 0˜5° C., continuing to stir for 1˜3 h, and suction filtrating obtained solid-liquid suspension to provide a novel crystalline form of Pantoprazole Sodium crystal after drying the product to constant weight.

Abstract: It discloses a new industrial crystallization method of Cefuroxime Sodium, wherein supercritical fluid extraction technology and traditional crystalline technology are combined to realize the recrystallization of Cefuroxime Sodium. Processes such as extraction, adsorption, crystallization and drying are carried out with a supercritical fluid, a solvent, an extraction cell and a crystallization tank to realize the recrystallization of Cefuroxime Sodium under a specific pressure at a specific temperature.

Abstract: A novel crystalline form is defined by diffraction angle 2?° of X-ray powder diffraction pattern and characteristic peak of differential scanning calorimetry (DSC). The novel crystalline form of Cefamandole Nafate is prepared as follows: adding Cefamandole Nafate in solid state to an organic solvent to form a suspension with a concentration of 0.04˜0.3 g/ml, stirring the suspension at 40˜50° C. for a period of time, and then cooling to 5˜15° C. at certain cooling rate, continuing to stir for a period of time, then suction filtrating the obtained suspension, the resulting filer cake is Cefamandole Nafate as wet product, which is dried to constant weight to provide the novel crystalline form of Cefamandole Nafate as final product.

Abstract: This invention provides a new preparation method of Clopidogrel Hydrogen Sulfate spherical crystal form I, using single 2-butanol as solvent, controlling the concentration, addition way and addition speed of sulfuric acid used to salify to shorten the process time, thus separating out Clopidogrel Hydrogen Sulfate from solution system stably with spherality. And the Clopidogrel Hydrogen Sulfate obtained complies with the requirements of the follow-up process on residual solvent, bulk density and mobility.

Abstract: The present invention relates to cefazolin sodium pentahydrate crystal and a method for assembly and preparation of the crystal molecule. The cefazolin sodium pentahydrate crystal molecule contains five water molecules, orthorhombic system, space group of C222(1), in which sodium ion is bonded to the cefazolin molecule with a coordinate bond. The method for assembly and preparation of cefazolin sodium pentahydrate crystal molecule are: adding a solvent to a reactor equipped with a jacket, adding cefazolin acid and a sodium salt, heating until the reaction solution is clear, stirring continuously, adjusting pH, upon the completion of the reaction, transferring the liquid into a jacketed crystallizer, adding crystal seeds or nucleating spontaneously, controlling cooling, slowly adding a antisolvent.